8 February 2018 - - Plainsboro, New Jersey-based global healthcare company Novo Nordisk has launched two new diabetes medications, Ozempic (semaglutide) injection 0.5 mg or 1 mg, and Fiasp (insulin aspart injection) 100 units/mL, at pharmacies across the US, the company said.
Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Fiasp is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Both medications received approval from the US Food and Drug Administration in 2017 and represent the latest advancements to Novo Nordisk's diabetes portfolio.
Novo Nordisk is a diabetes care specialist that is also focused on other serious chronic conditions such as hemophilia, growth disorders, and obesity. The company has nearly 5,000 employees in the US.